News
Hims & Hers Health Shocks Investors With a Long-Term Forecast, but Is the Stock a Buy?
Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer. The Motley Fool reaches millions of people every month through our premium investing solutions, free guidance and market analysis on Fool.com, top-rated podcasts, and non-profit The Motley Fool Foundation.
Andrew Dudum cofounded online pharmacy Hims & Hers eight years ago, when he was 27 years old. He’s now the latest to make a ...
Hims & Hers Health shares have surged 32.4% since Tuesday's session open. The stock is gaining following a standout ...
Telehealth company Hims & Hers reported first-quarter results late Monday that beat Wall Street estimates. But parts of the ...
The company reported adjusted earnings per share of $0.28 on revenue of $586 million – a significant rise compared to last ...
The stock of Hims & Hers Health Inc. (HIMS) fell more than 4% in after-hours trading after the telehealth company issued ...
Hims & Hers stock has risen by 20% after announcing a partnership to sell the popular weight-loss drug Wegovy.
Hims & Hers Health (NYSE:HIMS) reported first-quarter earnings on Monday after the market closed and rocketed 18% after ...
Hims & Hers ( HIMS 19.03%) stock soared 18.2% in trading on Tuesday after the company reported first-quarter revenue growth ...
Hims & Hers stock was trading lower but has since reversed and began trading higher after the company reported first-quarter ...
Hims & Hers management's 2030 guidance includes $6.5 billion in revenue and $1.3 billion in adjusted EBITDA. Read why HIMS ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback